SARS-CoV-2-antibodies may promote severe C...Immunoglobin G antibodies (IgG) produced in response to the SARS-CoV-2 spike protein appear to play a role in how COVID-19 can turn more severe in some cases. more ➔
Abingworth raises $582m for late-stage fun...International life sciences investment group Abingworth has closed a new clinical co-development fund at US$582m. more ➔
USA supports to temporarily waive IP of CO...The Biden administration has announced it will support the WHO proposal to temporarily waive intellectual property rights for COVID-19 vaccines to speed up vaccination. more ➔
Swiss Oculis SA raises $57m in Series CTopical ophthalmic therapies developer Oculis S.A. has closed a US$57m Series C financing to push development of its pipeline. more ➔
Mogrifiy completes Series A financing roun...Cell reprogramming specialist Mogrify Ltd has announced the second closing of its Series A financing of $17m, bringing the total raised to $33m in this round. more ➔
COVID-19 vaccine for poor countriesModerna Inc. has signed a COVID-19 vaccine supply agreement with vaccination alliance Gavi. more ➔
ADCendo ApS raises €51m in Series A fina...Danish ADCendo ApS will use the funds from a Series A investment to advance Antibody-Drug Conjugates (ADCs) entering cancer cells through endocytic receptors. more ➔
DNA Script bags DARPA fundingDNA Script will receive a $5m DARPA grant as part of the agency’s Nucleic Acids On-Demand World-Wide Program to prevent the next viral pandemic. more ➔
First malaria vaccine meets WHO efficacy c...Researchers at Novavax and from the University of Oxford reported an efficacy of 77% of their malaria vaccine, R21/Matrix-M from a Phase II trials in Burkina Faso. more ➔
European COVID-19 antibody enters Phase II...GSK’s and Vir Therapeutics COVID-19 antibody treatment VIR-7831 has entered Phase III testing within the UKs COVID-19 drug testing platform, AGILE more ➔
